Medterra takes an in-depth look at the pharmacology of CBC and how it could supercharge your health.
CBD’s popularity has been booming for over four years now and is becoming more mainstream by the day.
From CBD products hitting shelves of major pharmacy chains to professional athletes solidifying long term CBD sponsorships, the time for CBD is now and Medterra is no exception to this shift.
They supply premium hemp-derived CBD products that meet the highest purity standards and bring the highest levels of support for users all over the world.
Medterra stands out for its continuous innovation. Sometimes this bet leads the company to improve existing products… while other times it leads to creating new ones. Their products are offered in the form of isolate or ultra broad-spectrum CBD.
Broad Spectrum products are a blend of cannabinoids, terpenes and fatty acids that naturally occur in the hemp plant. An extraction process is utilised to remove the THC compound while maintaining substantial levels of other valuable cannabinoids like CBC.
Unlike isolate CBD, which contains only pure CBD, broad-spectrum products may produce heightened effects because they contain additional, compounds that work together.
As the research on cannabinoids progresses, cannabichromene has come into the spotlight for its pleasantly surprising effects. Nowadays it’s time for CBC to shine.
Here’s what you need to know about CBC: what it is, what it does, and how it could supercharge your health.
What is CBC?
Alongside CBN, CBC is one of the most powerful trace cannabinoids. It’s in the same family as CBD, CBN, CBG, THC, and over a hundred other cannabinoids. CBC is also one of the hemp’s “big six” cannabinoids, and though it’s not quite as popular as the other five yet, we’ve gotta admit that it has a pretty cool name.
CBC is similar to CBD and THC and it comes from the same precursor: CBG, or “the mother cannabinoid.” It also has a similar molecular mass and chemical formula.
How does CBC work?
Like CBD, CBC is non-psychotropic, meaning it won’t get you high. Unlike CBD, though, CBC has a greater binding affinity for pain-sensing receptors than it does for the “traditional” endocannabinoid system. It binds to TRPA1 receptors, TRPV receptors, and more.
Studies hint that CBC may reduce inflammation by helping your body to produce greater amounts of the endocannabinoid anandamide. Other research has shown that CBC’s anti-inflammatory benefits may carry over to skincare; another study found that CBC reduced the severity of acne.
In other words, the CBC you ingest goes to different molecular targets than CBD or THC do, and confers a slightly different set of benefits in the process.
CBC top health benefits
CBC research is just beginning to pick up. That means there aren’t all that many studies to choose from when sifting through the cannabinoid’s benefits.
What we do have, though, looks pretty promising. A 2014 review concluded that CBC “exert[s] a direct anti-proliferative effect on tumours of different origin.” Another study found that CBC may block the pain of collagen-related osteoarthritis. CBC may also contribute to the entourage effect.
Animal studies hint that CBC may benefit brain cell function. A 2013 study in mice found that CBC benefitted neural stem progenitor cells (NSPCs), a type of cell required for healthy brain function.
CBC’s anti-inflammatory properties may allow it to inhibit acne. One study found that CBC could suppress lipid overproduction within the skin’s sebaceous glands. This same study discovered that CBC reduced the conversion of unhealthy fats like arachidonic acid (AA) into inflammatory prostaglandins.
Medterra Ultra Broad Spectrum
How to use CBC
Since CBC-only hemp products are very rare, the easiest way to take CBC is to simply accept how it comes to us in nature. Medterra’s Ultra Broad Spectrum products have an industry-first 10:1 ratio of CBD to additional active cannabinoids, including CBC. This Ultra Broad Spectrum™ extract delivers a high-potency combination of active cannabinoids into convenient, long-lasting liquid capsules.
CBC can also be infused into all sorts of different stuff, including edibles, topicals, and capsules. As we said earlier, though, CBC-specific products are very rare, for now, but Medterra offers CBC products in a convenient and long-lasting variety of formats.
What difference can your CBC’s delivery method make?
Different CBC products stay in your body for different amounts of time. Vaping CBC may kick in fast, but its effects are also most transient. Oils and tinctures, on the other hand, are metabolized by the liver and essentially time-released over a longer period of time.
Medterra Ultra Broad Spectrum has an industry-first 10:1 ratio of CBD to additional active cannabinoids such as CBG, CBN, CBC, CBDV plus terpenes and flavonoids. Its Ultra Broad Spectrum extract delivers a high-potency combination of active cannabinoids in a convenient and long-lasting variety of formats.
The amount of CBC in a full spectrum product may be small, but don’t worry as only a small amount of CBC is needed for the entourage effect to kick in.
All in all, CBC is an underrated cannabinoid that’s definitely worth trying. It rounds out the effects of CBD perfectly and makes us suspect that nature really does know best after all.
Fair Trials and Last Prisoner Project seek to launch global cannabis justice project
Fair Trials’ Global CEO Norman L. Reimer to discuss the project at Cannabis Europa Conference in London on June 29.
A new initiative from Fair Trials and the Last Prisoner Project aims to redress the harm caused by cannabis prohibition and to secure relief for those in prison for cannabis-related convictions.
The criminal justice reform NGO, Fair Trials hopes that the industry will support its work in countries across the globe where cannabis laws are being liberalised. Through collaboration with local partners in appropriate jurisdictions, the Fair Trials project will identify people in need of legal assistance, and recruit, train and match volunteer lawyers to take on their cases.
Fair Trials has enlisted the help of the Last Prisoner Project, a coalition of cannabis industry leaders, executives and artists dedicated to bringing restorative justice to the cannabis sector.
More and more jurisdictions are allowing adults to use and distribute medical and recreational cannabis. But after decades of prohibition, countless people remain behind bars or continue to suffer the collateral consequences of a cannabis conviction.
“The injustice of cannabis prohibition has resulted in millions of people worldwide serving time in prison or being saddled with a cannabis conviction, which brings with it a lifetime of harmful consequences, ranging from education and employment opportunities to immigration status and parental rights,” said Fair Trials Global CEO, Norman L Reimer.
“Of course, these harmful effects of prohibition not only impact the individuals charged, but also their families and communities. And those effects have been borne disproportionately by minorities, communities of colour, and the socio-economically disadvantaged. Legalising cannabis alone does not equal justice. Together, we must address the ongoing harms of past prohibition and leave no cannabis prisoner behind.”
The project will be modelled on the US Cannabis Justice Initiative, a collaborative effort between the cannabis industry and volunteer lawyers in the United States. When Norman Reimer was the Executive Director of the National Association of Criminal Defense Lawyers (NACDL), he partnered with the Last Prisoner Project to establish the initiative.
“Key to the success of the initiative has been generous donations from legal cannabis companies and consumers nationwide,” said Last Prisoner Project Co-Founder Steve DeAngelo. “Fair Trials, with its global reach as the world’s criminal justice watchdog, is uniquely positioned to build and house the infrastructure that’s going to be needed.”
Tomorrow (29 June), Norman Reimer will address the Cannabis Europa Conference discussing the project. Mr Reimer will be part of a panel entitled ‘Leave No Cannabis Prisoner Behind,’ and will be joined on that panel by Mary Bailey, Managing Director at the Last Prisoner Project; Dr. Laura Garius, Policy Lead at Release; and Denzel Uba, an individual impacted by criminal cannabis prohibition.
TOWIE star Amy Childs launches CBD range in honour of Jorja Foundation
The product range sees a portion of the proceeds going to the Jorja Foundation.
TOWIE star Amy Childs launched her new CBD range this week, with a star-studded event that shone a spotlight on the story of six-year-old Jorja Emerson.
Amy Childs was joined by former Love Islanders, Amy Hart and Cara Delahoyde-Massey, alongside her co-stars, Frankie Essex, Tom Skinner, Carina Lepore, Saffron Lempriere and Mark Ferris, for a heart-warming event celebrating the launch of her new CBD Infused beauty range, Jorja Botanicals.
The signature collection sees a portion of the proceeds going to the Jorja Foundation, which was set up in honour of six-year-old medical cannabis patient, Jorja Emerson.
The event saw The Only Way Is Essex star Frankie Essex, break down in tears as she heard Jorja’s story. Frankie, who gave birth to twins four weeks ago, wiped her eyes when Robin Emerson, Jorja’s father, showed videos of the life-threatening seizures his daughter was suffering before they discovered medical cannabis.
Love Island star, Amy Hart has since taken to Instagram to spread the word about the latest political campaign that sees Childs and Emerson petitioning to make medical cannabis more widely available on the NHS.
The Jorja Botanicals range was inspired by Jorja, who was diagnosed with a rare chromosome abnormality called 1q43q44 deletion, which has a side effect of life-threatening seizures. Her illness resulted in her being admitted to intensive care on two separate occasions, where Robin was told that she may not make it.
To save his daughter’s life, Emerson knew that he had to dig deep and find a treatment that would not only help Jorja but ultimately go on to help others.
At the time it was still illegal to prescribe cannabis in the UK. Emerson joined the campaign to see medical cannabis legalised in the UK in November 2018, and Jorja’s was among the first children to be legally prescribed medicinal cannabis.
In 2021 he went on to create the Jorja Foundation – a charity set up to help other families and children going through the same battles that Robin had to face.
The Jorja Foundation’s core principles are to fund special needs equipment that is not funded through the health system, fund family counselling, private appointments and tests when a second opinion is needed, as well s cannabis-based treatment for children in the UK and to continue to campaign and educate for wider NHS access in the UK for cannabis-based medications.
Childs commented: “When I saw Robin & Jorja’s story on social media it broke my heart.
“As a mum, I couldn’t imagine the pain of being told to take my child home to say goodbye to them. I love that Robin has fought for Jorja & is now helping other families with the Jorja Foundation.
“I’m so happy that I can help the foundation by being the Creative Director of Jorja Botanicals. We have created some beautiful products for the whole family to enjoy. We will be donating a percentage of the proceeds to the foundation so that we can help as many families as possible. ”
Emerson added: “ This is the fruition of a lot of hard work over many months and I am extremely proud to launch what is the first family brand in this category. In the coming weeks, we will also be launching a ‘parent’ focused cosmetic range in partnership with our creative director Amy Childs and our premium line of tincture oils.”
South Africa launches first trial of cannabis for chronic pain
The study will test whether cannabis can replace opioids in the management of chronic pain.
South Africa’s first cannabis trial has launched after initial results “show promise” for the treatment as a replacement for opioids.
The study will involve 1,000 participants who have been taking opioids for pain management for at least three months and are prepared to switch to cannabis as an alternative.
Biodata is the brainchild of Dr Shiksha Gallow, a cannabis clinician and the principal investigator in the trial which took over 18 months to get official clearance.
Dr Gallow said the trial is set to be ground-breaking as South Africa’s first real-world study of medical cannabis. Researchers predict that it will provide much-needed insight into the link between cannabis genetics and patient outcomes.
Dr Gallow told Cannabiz Africa: “We are currently recruiting patients, and data-capturing all the questionnaires and feedback from the patients for the live Study. It has been fairly slow. However, more options have been introduced, as suggested by the patients in the pilot study.
“The pilot results of the study were very promising, as it showed 98 per cent of the patients have some sort of pain relief from the cannabis.
“We were able to wean these patients off their opioid treatment. In the pilot group of patients below the age of 55, it was shown this group preferred to smoke cannabis and patients older than 55 years preferred oil. The patients who smoked the cannabis had relief almost immediately, while the oil took some time to alleviate their pain.”
“Once we reach the sample size required and all of the relevant data has been collated, the results of the study will be published. We have currently renewed this study for another year, due to the initial slow uptake of research participants.”
Patients can apply to be research participants through the Biodata website.
Labat is expanding its footprint over the next few months with the introduction of CannAfrica kiosks in major shopping malls.
The company believes these will be the “ideal locations for physical sign-up points for the study”.
Labat said the kiosks will also serve as Biodata dispensaries and is engaging with a number of vape stores to do the same, although these would have to be subject to South African Health Products Regulatory Authority’s pharma-ethics requirements.
- CBD by British Cannabis™ launches in Selfridges
- Patient groups are key to a thriving cannabis industry – so support us, say campaigners
- 10 key patient takeaways from Cannabis Europa
- New fully digital cannabis dispensary launches in UK
- CiiTECH celebrates five years with five days of CBD offers
- Researchers are using firefly genes to understand cannabis biology
- News2 years ago
Community extends support to cannabis icon Rick Simpson
- News2 years ago
Cancer survivor claims cannabis oil helped her beat brain tumour
- Case Studies2 years ago
CBD oil and fibromyalgia – a case study
- News2 years ago
NHS lines up cannabis medicine manufacturing
- News2 years ago
Living with chronic fatigue – my CBD story
- News1 year ago
UK grants second licence to grow high-THC medical cannabis
- Insight2 years ago
I’ve gone from a wheelchair to walking thanks to cannabis
- Feature2 years ago
Medical cannabis could help long-term effects of COVID-19, says David Nutt